Valsartan therapy in heart failure after myocardial infarction

The role of endothelial dependent vasorelaxation

Hoang Thai, David Guarraia, Nicholle Johnson, Steven Goldman, Mohamed A. Gaballa

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Angiotensin II receptor blockade (ARB) increases vasorelaxation in heart failure by enhancing endothelial nitric oxide (NO). To determine the effects of valsartan on NO-mediated peripheral vascular function after myocardial infarction (MI), we treated adult male Sprague-Dawley rats immediately after MI with valsartan for 3 weeks (sham, n = 10; MI, n = 11) and 6 weeks (sham, n = 6; MI, n = 8). At both time points, valsartan lowered (P < 0.05) left ventricular (LV) systolic pressure (103 ± 4 and 107 ± 4 vs. 93 ± 3 and 85 ± 4 mm Hg, respectively) and LV end-diastolic pressure (25 ± 1 and 25 ± 2 to 13 ± 2 and 18 ± 3 mm Hg, respectively). Valsartan lowered (P < 0.05) LV dP/dt only at 6 weeks (4676 ± 168 and 4503 ± 232 vs. 4539 ± 281 and 3372 ± 417 mm Hg/sec); valsartan shortened (P < 0.05) the time constant of LV relaxation or tau only at 3 weeks (24.2 ± 1.8 and 26.5 ± 2.3 vs. 20.1 ± 0.7 and 23.8 ± 1.4 msec). At 6 weeks, the vasorelaxation response to acetycholine in aortic rings was decreased (P < 0.05) with MI and improved at acetycholine doses (10, 10, and 10; P < 0.06) with valsartan. Endothelial nitric oxide synthase (eNOS) protein was undetectable in aortic tissue from valsartan treated rats or from aortic tissue incubated with valsartan (2.5, 25, and 50 mg/mL). These data suggest that valsartan improves cardiac function after MI by modulating LV remodeling, decreasing LV end-diastolic pressure, and enhancing both LV diastolic and endothelial function. These effects are mediated, in part, by NO but upregulation of eNOS may not be required for improved systemic endothelial function in heart failure.

Original languageEnglish (US)
Pages (from-to)703-707
Number of pages5
JournalJournal of Cardiovascular Pharmacology
Volume50
Issue number6
DOIs
StatePublished - Dec 2007

Fingerprint

Valsartan
Vasodilation
Heart Failure
Myocardial Infarction
Nitric Oxide
Therapeutics
Nitric Oxide Synthase Type III
Blood Pressure
Ventricular Remodeling
Angiotensin Receptors
Ventricular Pressure

Keywords

  • Angiotensin II receptors
  • Conduit arteries
  • eNOS
  • Heart failure
  • Vasorelaxation

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Valsartan therapy in heart failure after myocardial infarction : The role of endothelial dependent vasorelaxation. / Thai, Hoang; Guarraia, David; Johnson, Nicholle; Goldman, Steven; Gaballa, Mohamed A.

In: Journal of Cardiovascular Pharmacology, Vol. 50, No. 6, 12.2007, p. 703-707.

Research output: Contribution to journalArticle

Thai, Hoang ; Guarraia, David ; Johnson, Nicholle ; Goldman, Steven ; Gaballa, Mohamed A. / Valsartan therapy in heart failure after myocardial infarction : The role of endothelial dependent vasorelaxation. In: Journal of Cardiovascular Pharmacology. 2007 ; Vol. 50, No. 6. pp. 703-707.
@article{6e8ea8a79c8e49e9aadd177ba754afca,
title = "Valsartan therapy in heart failure after myocardial infarction: The role of endothelial dependent vasorelaxation",
abstract = "Angiotensin II receptor blockade (ARB) increases vasorelaxation in heart failure by enhancing endothelial nitric oxide (NO). To determine the effects of valsartan on NO-mediated peripheral vascular function after myocardial infarction (MI), we treated adult male Sprague-Dawley rats immediately after MI with valsartan for 3 weeks (sham, n = 10; MI, n = 11) and 6 weeks (sham, n = 6; MI, n = 8). At both time points, valsartan lowered (P < 0.05) left ventricular (LV) systolic pressure (103 ± 4 and 107 ± 4 vs. 93 ± 3 and 85 ± 4 mm Hg, respectively) and LV end-diastolic pressure (25 ± 1 and 25 ± 2 to 13 ± 2 and 18 ± 3 mm Hg, respectively). Valsartan lowered (P < 0.05) LV dP/dt only at 6 weeks (4676 ± 168 and 4503 ± 232 vs. 4539 ± 281 and 3372 ± 417 mm Hg/sec); valsartan shortened (P < 0.05) the time constant of LV relaxation or tau only at 3 weeks (24.2 ± 1.8 and 26.5 ± 2.3 vs. 20.1 ± 0.7 and 23.8 ± 1.4 msec). At 6 weeks, the vasorelaxation response to acetycholine in aortic rings was decreased (P < 0.05) with MI and improved at acetycholine doses (10, 10, and 10; P < 0.06) with valsartan. Endothelial nitric oxide synthase (eNOS) protein was undetectable in aortic tissue from valsartan treated rats or from aortic tissue incubated with valsartan (2.5, 25, and 50 mg/mL). These data suggest that valsartan improves cardiac function after MI by modulating LV remodeling, decreasing LV end-diastolic pressure, and enhancing both LV diastolic and endothelial function. These effects are mediated, in part, by NO but upregulation of eNOS may not be required for improved systemic endothelial function in heart failure.",
keywords = "Angiotensin II receptors, Conduit arteries, eNOS, Heart failure, Vasorelaxation",
author = "Hoang Thai and David Guarraia and Nicholle Johnson and Steven Goldman and Gaballa, {Mohamed A.}",
year = "2007",
month = "12",
doi = "10.1097/FJC.0b013e318159378b",
language = "English (US)",
volume = "50",
pages = "703--707",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Valsartan therapy in heart failure after myocardial infarction

T2 - The role of endothelial dependent vasorelaxation

AU - Thai, Hoang

AU - Guarraia, David

AU - Johnson, Nicholle

AU - Goldman, Steven

AU - Gaballa, Mohamed A.

PY - 2007/12

Y1 - 2007/12

N2 - Angiotensin II receptor blockade (ARB) increases vasorelaxation in heart failure by enhancing endothelial nitric oxide (NO). To determine the effects of valsartan on NO-mediated peripheral vascular function after myocardial infarction (MI), we treated adult male Sprague-Dawley rats immediately after MI with valsartan for 3 weeks (sham, n = 10; MI, n = 11) and 6 weeks (sham, n = 6; MI, n = 8). At both time points, valsartan lowered (P < 0.05) left ventricular (LV) systolic pressure (103 ± 4 and 107 ± 4 vs. 93 ± 3 and 85 ± 4 mm Hg, respectively) and LV end-diastolic pressure (25 ± 1 and 25 ± 2 to 13 ± 2 and 18 ± 3 mm Hg, respectively). Valsartan lowered (P < 0.05) LV dP/dt only at 6 weeks (4676 ± 168 and 4503 ± 232 vs. 4539 ± 281 and 3372 ± 417 mm Hg/sec); valsartan shortened (P < 0.05) the time constant of LV relaxation or tau only at 3 weeks (24.2 ± 1.8 and 26.5 ± 2.3 vs. 20.1 ± 0.7 and 23.8 ± 1.4 msec). At 6 weeks, the vasorelaxation response to acetycholine in aortic rings was decreased (P < 0.05) with MI and improved at acetycholine doses (10, 10, and 10; P < 0.06) with valsartan. Endothelial nitric oxide synthase (eNOS) protein was undetectable in aortic tissue from valsartan treated rats or from aortic tissue incubated with valsartan (2.5, 25, and 50 mg/mL). These data suggest that valsartan improves cardiac function after MI by modulating LV remodeling, decreasing LV end-diastolic pressure, and enhancing both LV diastolic and endothelial function. These effects are mediated, in part, by NO but upregulation of eNOS may not be required for improved systemic endothelial function in heart failure.

AB - Angiotensin II receptor blockade (ARB) increases vasorelaxation in heart failure by enhancing endothelial nitric oxide (NO). To determine the effects of valsartan on NO-mediated peripheral vascular function after myocardial infarction (MI), we treated adult male Sprague-Dawley rats immediately after MI with valsartan for 3 weeks (sham, n = 10; MI, n = 11) and 6 weeks (sham, n = 6; MI, n = 8). At both time points, valsartan lowered (P < 0.05) left ventricular (LV) systolic pressure (103 ± 4 and 107 ± 4 vs. 93 ± 3 and 85 ± 4 mm Hg, respectively) and LV end-diastolic pressure (25 ± 1 and 25 ± 2 to 13 ± 2 and 18 ± 3 mm Hg, respectively). Valsartan lowered (P < 0.05) LV dP/dt only at 6 weeks (4676 ± 168 and 4503 ± 232 vs. 4539 ± 281 and 3372 ± 417 mm Hg/sec); valsartan shortened (P < 0.05) the time constant of LV relaxation or tau only at 3 weeks (24.2 ± 1.8 and 26.5 ± 2.3 vs. 20.1 ± 0.7 and 23.8 ± 1.4 msec). At 6 weeks, the vasorelaxation response to acetycholine in aortic rings was decreased (P < 0.05) with MI and improved at acetycholine doses (10, 10, and 10; P < 0.06) with valsartan. Endothelial nitric oxide synthase (eNOS) protein was undetectable in aortic tissue from valsartan treated rats or from aortic tissue incubated with valsartan (2.5, 25, and 50 mg/mL). These data suggest that valsartan improves cardiac function after MI by modulating LV remodeling, decreasing LV end-diastolic pressure, and enhancing both LV diastolic and endothelial function. These effects are mediated, in part, by NO but upregulation of eNOS may not be required for improved systemic endothelial function in heart failure.

KW - Angiotensin II receptors

KW - Conduit arteries

KW - eNOS

KW - Heart failure

KW - Vasorelaxation

UR - http://www.scopus.com/inward/record.url?scp=37348999920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37348999920&partnerID=8YFLogxK

U2 - 10.1097/FJC.0b013e318159378b

DO - 10.1097/FJC.0b013e318159378b

M3 - Article

VL - 50

SP - 703

EP - 707

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 6

ER -